Uncategorized

Dabrafenib, Trametinib Active in Pediatric Glioma With BRAF V600

1 year ago
by David Miller
953 Views

THURSDAY, Sept. 21, 2023 — Dabrafenib plus trametinib results in significantly more responses and longer progression-free survival than standard chemotherapy for pediatric patients with low-grade glioma with BRAF V600 mutations, according to a…

THURSDAY, Sept. 21, 2023 — Dabrafenib plus trametinib results in significantly more responses and longer progression-free survival than standard chemotherapy for pediatric patients with low-grade glioma with BRAF V600 mutations, according to a…Original Article

You may also like

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts

Don`t Leave Yet!

Thank you!

[mwai_chat window="true" fullscreen="true"]